ATE366568T1 - Aerosolformulierungen von salmeterol xinafoate - Google Patents

Aerosolformulierungen von salmeterol xinafoate

Info

Publication number
ATE366568T1
ATE366568T1 AT99920757T AT99920757T ATE366568T1 AT E366568 T1 ATE366568 T1 AT E366568T1 AT 99920757 T AT99920757 T AT 99920757T AT 99920757 T AT99920757 T AT 99920757T AT E366568 T1 ATE366568 T1 AT E366568T1
Authority
AT
Austria
Prior art keywords
formulations
salmeterol xinafoate
xinafoate
salmeterol
aerosol formulations
Prior art date
Application number
AT99920757T
Other languages
English (en)
Inventor
Simon Cooper
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10830947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366568(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE366568T1 publication Critical patent/ATE366568T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99920757T 1998-04-24 1999-04-23 Aerosolformulierungen von salmeterol xinafoate ATE366568T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9808802.4A GB9808802D0 (en) 1998-04-24 1998-04-24 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ATE366568T1 true ATE366568T1 (de) 2007-08-15

Family

ID=10830947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99920757T ATE366568T1 (de) 1998-04-24 1999-04-23 Aerosolformulierungen von salmeterol xinafoate

Country Status (9)

Country Link
US (1) US6613307B1 (de)
EP (1) EP1073429B1 (de)
JP (1) JP2002512952A (de)
AT (1) ATE366568T1 (de)
AU (1) AU3821399A (de)
DE (1) DE69936515T2 (de)
ES (1) ES2289811T3 (de)
GB (1) GB9808802D0 (de)
WO (1) WO1999055319A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234694T3 (es) * 1999-11-23 2005-07-01 Glaxo Group Limited Formulaciones farmaceuticas de salmeterol.
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6485707B2 (en) * 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6596262B2 (en) 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0208742D0 (en) * 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US6915966B2 (en) * 2003-01-29 2005-07-12 Specialty Minerals (Michigan) Inc. Apparatus for the gunning of a refractory material and nozzles for same
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1663159A4 (de) * 2003-09-10 2010-06-09 Map Pharmaceuticals Inc Aerosol-formulierungen zur abgabe von dihydroergotamin an den systemischen kreislauf durch pulmonale inhalation
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1732526A2 (de) * 2004-03-12 2006-12-20 Cipla Ltd. Salmeterol-formulierungen zur inhalation
JP4340685B2 (ja) * 2004-03-30 2009-10-07 パイオニア株式会社 音声認識装置及び音声認識方法
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
EP1753734A1 (de) 2004-05-05 2007-02-21 Renopharm Ltd. Stickstoffmonoxidspender und anwendungen davon
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
GB0418791D0 (en) * 2004-08-23 2004-09-22 Glaxo Group Ltd Novel process
US7854397B2 (en) * 2005-01-21 2010-12-21 Specialty Minerals (Michigan) Inc. Long throw shotcrete nozzle
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
ES2452965T3 (es) 2007-09-05 2014-04-03 Rigel Pharmaceuticals, Inc. Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina
EP3620154A1 (de) 2009-02-06 2020-03-11 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
SG178036A1 (en) 2009-07-15 2012-03-29 Theravance Inc Crystalline freebase forms of a biphenyl compound
US9877967B2 (en) 2010-01-26 2018-01-30 Endacea, Inc. Methods and pharmaceutical compositions for preventing and treating renal impairment
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
WO2011145109A1 (en) * 2010-05-20 2011-11-24 Sun Pharma Advanced Research Company Ltd., Dry powder inhalation composition
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
WO2012032546A2 (en) 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
WO2015199626A1 (en) * 2014-06-27 2015-12-30 World Medicine İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ STABLE AEROSOL FORMULATIONS OF β2- ADRENERGIC AGONISTS
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク. 血液脳関門を透過性にする方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706598A (en) * 1970-07-15 1972-12-19 Cpc International Inc Solid,glass-like starch hydrolysates having high densities
JPH05500229A (ja) * 1991-04-12 1993-01-21 東レ株式会社 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
NZ246046A (en) * 1991-12-12 1995-12-21 Glaxo Group Ltd Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5301664A (en) 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
ATE387925T1 (de) * 1994-09-21 2008-03-15 Nektar Therapeutics Vorrichtung und verfahren zum dispergieren von trockenen pulvermedikamenten
JP2860951B2 (ja) * 1995-01-12 1999-02-24 株式会社萩原技研 抗菌性ポリマー組成物
EP1366777B1 (de) * 1995-04-14 2005-06-15 SmithKline Beecham Corporation Dosierinhalator für Salmeterol
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5977010A (en) * 1995-06-15 1999-11-02 Engelhard Corporation Shaped hydrogenation catalyst and processes for their preparation and use
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device

Also Published As

Publication number Publication date
EP1073429B1 (de) 2007-07-11
AU3821399A (en) 1999-11-16
JP2002512952A (ja) 2002-05-08
WO1999055319A1 (en) 1999-11-04
DE69936515T2 (de) 2007-11-22
GB9808802D0 (en) 1998-06-24
DE69936515D1 (de) 2007-08-23
EP1073429A1 (de) 2001-02-07
US6613307B1 (en) 2003-09-02
ES2289811T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
DE69936515D1 (de) Aerosolformulierungen von salmeterol xinafoate
BR9406995A (pt) Carboxilato de I-hidroxi-2-naftaleno (xinafoato) de 4- hidroxi- 1-[[[6-(4-fenilbutoxi)hexil]amino]metil]-1,3- benzenodimetanol (salmeterol) xinafoato de salmeterol e composição farmacêutica
TR200100144T2 (tr) Farmasötik aerosol formülasyonu
HUP0401619A3 (en) Phenethanolamine derivatives, process for their preparation and pharmaceutical composition containing them
MY194689A (en) Compositions containing fluorine substituted olefins and method and system using same
DK0717617T3 (da) Mikropartikler indeholdende aktive bestanddele og gas
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
IL153997A0 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AR020392A1 (es) Formulaciones microencapsuladas.
ZA986931B (en) Aqueous aerosol formulations comprising biologically active macromolecules and method for the generation of such aerosols.
MXPA03006538A (es) Nuevos derivados de urea, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
HUP0204202A3 (en) Ibuprofen containing active agent preparation, process for its preparation and pharmaceutical compositions containing it
HUP0401201A3 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
IL163812A (en) Immunizing composition, antigenic product and isolated antigenic peptide for inducing an immune response against beta-secretase cleavage site of amyloid the precursor protein
HUP0301817A3 (en) Kahalalide compounds, process for preparing thereof, pharmaceutical compositions comprising them and their use
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
WO2005063194A3 (fr) Procede d'innoformulation d'une base galenique biocompatible
MXPA03009984A (es) PREPARACION PARA LA REMOCIoN DE MATERIAL QUERATINOSO ANORMAL.
DK1474491T3 (da) Anvendelse af antiadhæsive emballagematerialer til emballering af kemikalier og levnedsmidler
HUP0401369A3 (en) Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
HUP0303195A3 (en) O-substituted 6-methyl-tramadol derivatives, process for their preparation and pharmaceutical compositions containing them
DK1118610T3 (da) Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
HUP0303804A3 (en) Ligands of the avss6 integrin, process for their preparation, their use and pharmaceutical compositions containing them
WO2002000191A3 (de) Bdellosomen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties